FindTrial
Sign In

ATG-010

DRUG3 trials

Sponsors

Antengene Corporation, Qi Zhou

Conditions

1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDiffuse Large B-cell LymphomaIndolent Non-Hodgkin LymphomaRelapse/Refractory Multiple Myeloma

Phase 1

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
TerminatedNCT05265975
Antengene CorporationDiffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
Start: 2022-04-07End: 2024-12-31Updated: 2025-06-09

Phase 2

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
CompletedNCT03944057
Antengene CorporationRelapse/Refractory Multiple Myeloma
Start: 2019-09-02End: 2022-02-25Updated: 2023-06-15
A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )
NCT04998760
Qi Zhou1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
Start: 2021-08-03End: 2024-04-09Target: 96Updated: 2021-08-10

Related Papers

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors.
2023-12-061 citations
Update of Swatch Study: Selinxor Combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL)
Blood2023-11-02
SELINXOR COMBINED WITH LENALIDOMIDE AND RITUXIMAB (R2) IN ADULTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) AND INDOLENT NON‐HODGKIN'S LYMPHOMA (INHL) (SWATCH STUDY)
Hematological Oncology2023-06-01
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
BMC Medicine2022-04-0525 citations
Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
Journal of Clinical Oncology2021-05-203 citations